A detailed history of Janus Henderson Group PLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 17,716 shares of NUVL stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,716
Previous 12,716 39.32%
Holding current value
$1.68 Million
Previous $964,000 87.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.44 - $112.17 $337,200 - $560,850
5,000 Added 39.32%
17,716 $1.81 Million
Q2 2024

Aug 14, 2024

SELL
$62.76 - $81.61 $8,409 - $10,935
-134 Reduced 1.04%
12,716 $964,000
Q1 2024

May 15, 2024

BUY
$72.35 - $88.99 $506 - $622
7 Added 0.05%
12,850 $964,000
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $189,320 - $358,289
4,463 Added 53.26%
12,843 $945,000
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $1.9 Million - $2.42 Million
-48,536 Reduced 85.28%
8,380 $385,000
Q2 2023

Aug 14, 2023

SELL
$23.58 - $44.68 $4.27 Million - $8.09 Million
-181,038 Reduced 76.08%
56,916 $2.4 Million
Q1 2023

May 15, 2023

SELL
$25.42 - $33.52 $138,818 - $183,052
-5,461 Reduced 2.24%
237,954 $6.21 Million
Q4 2022

Feb 14, 2023

SELL
$18.46 - $36.37 $2.87 Million - $5.65 Million
-155,241 Reduced 38.94%
243,415 $7.25 Million
Q3 2022

Nov 14, 2022

SELL
$13.55 - $19.92 $11.5 Million - $16.9 Million
-848,509 Reduced 68.04%
398,656 $7.75 Million
Q2 2022

Aug 15, 2022

SELL
$7.4 - $15.07 $667,924 - $1.36 Million
-90,260 Reduced 6.75%
1,247,165 $16.9 Million
Q1 2022

May 16, 2022

SELL
$11.65 - $19.57 $939,246 - $1.58 Million
-80,622 Reduced 5.69%
1,337,425 $18.6 Million
Q4 2021

Feb 14, 2022

SELL
$18.01 - $30.1 $178,821 - $298,862
-9,929 Reduced 0.7%
1,418,047 $26.1 Million
Q3 2021

Nov 16, 2021

BUY
$18.25 - $38.35 $26.1 Million - $54.8 Million
1,427,976 New
1,427,976 $30.2 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.08B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.